Retatrutide TRIUMPH-1 Cardiometabolic Outcomes Explained

What the TRIUMPH-1 Secondary Data Showed (And Why It Matters)

The May 2026 TRIUMPH-1 topline told the weight-loss story: 28.3% average body weight loss at 80 weeks on 12mg. The June 6, 2026 ADA presentation told a different one. Alongside the TRANSCEND-T2D-1 diabetes readout, Lilly released the full TRIUMPH-1 secondary endpoint package, the cardiometabolic and comorbidity measures that show what a triple-agonist does to the conditions that travel with obesity. That is the focus of this page. For the dose-by-dose weight-loss topline (28.3% at 80 weeks, 30.3% in the 104-week extension subgroup), see the full TRIUMPH-1 phase 3 results guide.

These secondary endpoints matter because obesity rarely arrives alone. High triglycerides, elevated blood pressure, knee osteoarthritis, and obstructive sleep apnea cluster around it. A weight-loss drug that also moves those markers is a different proposition than one that only changes the number on the scale, and the TRIUMPH-1 secondary data are the first Phase 3 evidence of how far retatrutide reaches.

Trial Design Recap (Brief)

TRIUMPH-1 (NCT05929066) enrolled 2,339 adults with obesity or overweight, randomized to three active dose arms (4mg, 9mg, 12mg) versus placebo over an 80-week master protocol, with nested knee osteoarthritis and obstructive sleep apnea substudies built into the design. The figures below are 80-week results on the 12mg arm. The Phase 3 program was built on the earlier Phase 2 trial of retatrutide published in the New England Journal of Medicine in 2023, which first established the triple agonist's weight-loss and metabolic signal over 48 weeks (Jastreboff et al., 2023). Full design detail, including enrollment criteria and the wider TRIUMPH program, lives in the TRIUMPH program overview.

Retatrutide Cardiometabolic Secondary Outcomes at 80 Weeks

Four cardiometabolic secondary endpoints anchor the TRIUMPH-1 cardiometabolic outcomes story, all measured on the 12mg arm at the 80-week endpoint. These are the article's core original contribution, drawn directly from the June 6 ADA presentation.

The triglyceride figure is the one worth a second look. A 41.0% reduction is large for any obesity drug, and it is not simply a downstream effect of losing weight. It points at the mechanism, which is where the glucagon receptor comes in.

Why Glucagon Receptor Agonism Drives These Outcomes

Retatrutide is a triple agonist: it activates the GLP-1, GIP, and glucagon receptors at once. Each arm does different work. GLP-1 agonism drives satiety and supports insulin secretion. GIP agonism shapes how energy gets partitioned, including adipose uptake. The glucagon receptor is the arm the other GLP-1 drugs do not have, and it changes the metabolic picture. Glucagon signaling increases hepatic lipid catabolism, meaning the liver burns more fat, and it raises energy expenditure through thermogenesis on top of the appetite effect.

That hepatic fat-burning is the most plausible explanation for a 41.0% triglyceride drop. Tirzepatide lacks the glucagon-receptor arm that is thought to drive hepatic lipid catabolism, which may explain differences in lipid effects between the two molecules. The waist circumference reduction follows the same logic: shifting visceral fat is partly an appetite story and partly an energy-expenditure story, and the glucagon component is thought to contribute to both. For the receptor biology in depth, see how retatrutide works.

Comparing Cardiometabolic Profiles Across the Class

It helps to place these numbers in the context of the wider class, with one firm caveat. On weight loss, the lexicon-verified benchmarks are 28.3% for retatrutide at 80 weeks (TRIUMPH-1, 12mg), 20.9% for tirzepatide (SURMOUNT-1, 15mg), and 14.9% for semaglutide. The glucagon receptor component, which is absent in both tirzepatide (GIP and GLP-1) and semaglutide (GLP-1 only), is the leading proposed mechanism for the 41.0% triglyceride reduction. That is a mechanistic point, not a head-to-head result.

Responder Rates: Who Reaches What Threshold?

An average can hide as much as it reveals. The 28.3% mean weight loss in TRIUMPH-1 is built from a spread of individual results, and the responder analysis shows how wide that spread runs. At 80 weeks, 45.3% of participants on 12mg retatrutide lost 30% or more of their body weight. A 30% loss sits in the range historically associated with bariatric surgery, reached here with a once-weekly injection.

The BMI data tell a parallel story. By 80 weeks, 65.3% of the 12mg group had reached a BMI below 30, crossing out of the clinical obesity category entirely. Nearly two-thirds of participants moved from obese to overweight or normal weight. These responder rates give a more honest read on what the drug did across the trial population than the single 28.3% average, which sits well below what the strongest responders achieved.

Responder thresholds matter for the regulatory case too. A drug that pushes a large fraction of patients past surgery-range outcomes carries a stronger story to the FDA than one that nudges everyone modestly. For the dose-by-dose averages that sit underneath these responder rates, the phase 3 results guide has the full breakdown.

Comorbidity Outcomes: Knee OA and Sleep Apnea Nested Studies

Two of the TRIUMPH-1 cardiometabolic outcomes came from pre-specified nested substudies, not the full 2,339-participant population. This distinction matters: the knee osteoarthritis and sleep apnea results below come from smaller subgroups enrolled within the master protocol, so they describe targeted subpopulations rather than the whole trial.

Knee Osteoarthritis (WOMAC Pain Subscale)

In the knee osteoarthritis nested subgroup, retatrutide 12mg reduced WOMAC knee pain by up to 73.1%, a drop of up to 4.3 points, at 80 weeks. WOMAC is a standard scale for measuring osteoarthritis pain and function, so a reduction of this size translates to a meaningful change in day-to-day knee pain for the people in that subgroup.

Keep this distinct from TRIUMPH-4. TRIUMPH-4 (NCT05931367) is the dedicated obesity-plus-osteoarthritis Phase 3 trial, and it reported first, in December 2025. The TRIUMPH-1 figure above comes from a nested osteoarthritis basket inside the general obesity master protocol, a different though overlapping subpopulation. For the TRIUMPH-4 data and how the two trials relate, see the TRIUMPH program overview.

Obstructive Sleep Apnea (Apnea-Hypopnea Index)

In the obstructive sleep apnea nested subgroup, retatrutide 12mg reduced the apnea-hypopnea index by up to 60.6%, a fall of up to 36.1 events per hour, at 80 weeks. The apnea-hypopnea index counts breathing interruptions per hour of sleep, so a reduction of this size is a large shift in apnea severity, most plausibly driven by the weight loss itself reducing airway obstruction.

The clinical context here is concrete. Zepbound (tirzepatide) received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, so there is a clear regulatory precedent for a GLP-1-class drug carrying an OSA indication. Retatrutide's nested OSA data put it on a similar path, though it remains a substudy result inside a single trial. The wider trial context is in the TRIUMPH program overview.

Watch: Clinical Coverage of the TRIUMPH-1 Data

This HCPLive segment walks clinicians through the TRIUMPH-1 weight-loss and secondary outcomes, a useful complement to the figures above.

What the Cardiometabolic Outcomes Mean for the FDA Filing

The secondary outcomes broaden retatrutide's regulatory story beyond weight loss alone. The comorbidity data, knee osteoarthritis pain and sleep apnea severity, support potential nested indications alongside the primary obesity filing, and the cardiometabolic improvements strengthen the benefit case for the core obesity submission. A drug that lowers triglycerides, blood pressure, and apnea severity carries more than a cosmetic claim into review.

None of this changes the present status: retatrutide is investigational and not FDA-approved for any indication as of June 2026. For the regulatory timeline and what investigational status means for access, see is retatrutide FDA approved.